ORVIMID, created in 2003 (United States), from
126 sister brands
and 17478 competing brands.
ORVIMID is a brand of Celgene, listed on the stock exchange of New York.
ORVIMID is part of the Drug Manufacturers activity sector.
Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.